$GDRX

GoodRx launched a family healthcare subscription, Companion, for $24.99/month, offering 250 generic medications and discounted medical services. The program will launch as an employer benefit in 2027. CEO Wendy Barnes cited rising healthcare costs and insurance gaps as key drivers. GoodRx's subscription revenue grew 39% YoY in Q2, with Companion uptake exceeding expectations. Employers expect healthcare costs to rise 9.2% in 2027, per the Business Group on Health.

GoodRx (GDRX) launched the Companion Family Plan, extending its healthcare subscription to cover the entire household, including pets. The plan, priced at $24.99/month or $16.99/month annually, covers up to four dependents and offers free generic medications, discounts on healthcare services, and online care visits. The company aims to expand its subscription offerings and support retail pharmacy partners.

Evolent Health (EVH) reported Q2 revenue of $652.5M, up 46.9% YoY, beating estimates. Astrana Health (ASTH) reported $972.5M, up 48.5%, missing estimates. Tandem Diabetes (TNDM) reported $254.6M, up 5.8%, in line with estimates. GoodRx (GDRX) reported $200.4M, down 1.3%, beating estimates. All stocks rose post-earnings.

Bank of America Securities maintained a Buy rating on Jazz Pharmaceuticals (JAZZ) with a $307 price target, while TipRanks upgraded it to Buy with a $282 target. GoodRx Holdings (GDRX) was kept at Sell with a $2.65 target by the same analyst, and Barclays also rated it Sell with a $4 target.

FRANCISCO PARTNERS IV, L.P. sold 1,567,044 indirectly-held shares of GoodRx Holdings, Inc. (GDRX) at an average of $3.50 ($3.44–$3.51, $5.48M total) across 8 trades over 2026-08-24 to 2026-08-26. Filed jointly with FRANCISCO PARTNERS IV-A, L.P. (10% owner), Francisco Partners GP IV, L.P. (10% owner), Francisco Partners GP IV Management Ltd (10% owner) and Francisco Partners Management, LP (10% owner).

FRANCISCO PARTNERS IV, L.P. sold 1,193,951 indirectly-held shares of GoodRx Holdings, Inc. (GDRX) at an average of $3.52 ($3.50–$3.53, $4.20M total) across 6 trades over 2026-08-19 to 2026-08-21. Filed jointly with FRANCISCO PARTNERS IV-A, L.P. (10% owner), Francisco Partners GP IV, L.P. (10% owner), Francisco Partners GP IV Management Ltd (10% owner) and Francisco Partners Management, LP (10% owner).

GoodRx reported Q2 revenue of $200.4M, down 1%, and raised its full-year outlook, citing a projected 70% revenue increase from Pharma Direct. Oscar Health reported first-half 2026 results with revenue up 70% to $4.9B and record profitability, attributing gains to its AI platform and “Oswal” tools. Both cited shifting consumer insurance needs.

GoodRx (NASDAQ:GDRX) reported Q2 CY2026 revenue of $200.4 million, down 1.3% year over year, but 3.5% above Wall Street estimates. Full-year revenue guidance was $797.5 million at the midpoint, 2.8% above analysts’ views. Non-GAAP EPS was $0.08, in line with consensus, and the stock rose 5.4% to $3.45.

GoodRx Holdings, Inc. (GDRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earlies

GoodRx Holdings, Inc. (GDRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 GOODRX REPORTS SECOND QUARTER 2026 RESULTS Pharma Direct and Subscription Revenue Increased 76% and 39% , Respectively, Year-Over-Year Company Raises Full-Year 2026 Revenue and Adjusted EBITDA Expectations SANTA MONICA, Calif. -- ( August 5, 2026 ) -- GoodRx Holdings